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Abstract
Background:  To assess the role of Fractionated Stereotactic Radiotherapy (FSRT) in the
management of ependymomas.
Methods: From January 1992 to July 2003, FSRT was performed in 19 patients with histologically
confirmed ependymomas. The median age was 15 years, 5 patients were younger than 4 years of
age.
Twelve patients received FSRT as primary postoperative radiotherapy after surgical resection. In 6
patients irradiation of the posterior fossa was performed with a local boost to the tumor bed, and
in 4 patients the tumor bed only was irradiated. In 7 patients FSRT was performed as re-irradiation
for tumor progression. This patient group was analyzed separately. A median dose of 54 Gy was
prescribed in a median fractionation of 5 × 1.8 Gy per week for primary RT using 6 MeV photons
with a linear accelerator. For FSRT as re-irradiation, a median dose of 36 Gy was applied. All
recurrent tumors were localized within the former RT-field.
Results: The 5- and 10-year overall survival rates were 77% and 64%, respectively. Patients treated
with FSRT for primary irradiation showed an overall survival of 100% and 78% at 3 and 5 years after
irradiation of the posterior fossa with a boost to the tumor bed, and a survival rate of 100% at 5
years with RT of the tumor bed only. After re-irradiation with FSRT, survival rates of 83% and 50%
at 3-and 5 years, respectively, were obtained.
Progression-free survival rates after primary RT as compared to re-irradiation were 64% and 60%
at 5 years, respectively.
FSRT was well tolerated by all patients and could be completed without interruptions due to side
effects. No severe treatment related toxicity > CTC grade 2 for patients treated with FSRT could
be observed.
Conclusion: The present analysis shows that FSRT is well tolerated and highly effective in the
management of ependymal tumors. The rate of recurrences, especially at the field border, is not
increased as compared to conventional radiotherapy consisting of craniospinal irradiation and a
local boost to the posterior fossa.
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Background
Ependymomas (EP) originate from ependymal cells of the
wall of the cerebral ventricles, the central canal of the spi-
nal cord, and from ependymal remnants in the filum ter-
minale, the choroid plexus or the white matter adjacent to
the highly angulated ventricular surface [1]. Additionally,
ependymal neoplasms can be caused by the migration of
fetal ependymal cell residuals from periventricular areas
into the brain parenchyma [2].
The group accounts for 3% of all intracranial neoplasms,
and they are the third most common tumor diagnosed in
children. About 10% of childhood central nervous system
tumors are ependymomas (EPs), and 50% of patients are
younger than 3 years of age [3-5]. Most ependymal tumors
arise infratentorially, commonly in the area of the fourth
ventricle; about 10–15% arise along the spinal axis [3-7].
EPs constitute 3–9% of all neuroepithelial tumors, and
50–60% of spinal gliomas [1,3,8-12].
The World Health Organization (WHO) classification of
central nervous system tumors recognizes various groups
of EP: Subependymomas (WHO Grade I), ependymomas
(WHO Grade II), and anaplastic ependymomas (WHO
Grade III) [8]. The biological activity of EP is related to the
intracranial location; infratentorial tumors show a higher
mitotic activity than supratentorial tumors [13].
The management of ependymal tumors is discussed con-
troversially. Commonly, multimodality treatment includ-
ing surgery and radiotherapy is performed. Research is
focusing on precision RT techniques enabling local dose
escalation. In the past, craniospinal irradiation (CSI) was
recommended to be the standard radiotherapeutic
approach. Bloom et al. recommend CSI especially for high
grade tumors localized infratentorially [14]. However,
more and more studies have shown that localized irradia-
tion of the posterior fossa or even volumes as small as the
tumor bed and a 1.5–2 cm safety margin are equally effec-
tive [12,24,34,49]. As a positive dose-effect-relationship
with regard to the prescribed RT dose is known for EP [15-
17], high precision radiotherapy techniques such as frac-
tionated stereotactic radiotherapy (FSRT) might be bene-
ficial in the treatment of patients with EP since high local
doses can be applied to a defined target volume while
sparing surrounding normal tissues. However, the role of
FSRT is not yet clearly defined in the treatment of EP. The
present study reports our results of locoregional RT for
patients with EP using FSRT, analyzes prognostic factors
and reflects results and recommendations found in the lit-
erature.
Methods
Study population
From January 1992 to December 2003, 17 patients with
histologically confirmed EP were treated with FSRT.
The data presented in this analysis were acquired retro-
spectively and anonymously; therefore, no official
approval by the local ethics committee was necessary.
All patients had received a complete work-up after pri-
mary diagnosis, including MRI of the brain, spine as well
as a lumbar puncture with craniospinal fluid cytology to
allow for exact staging. The degree of surgical resection
was based on the neurosurgeon's opinion as well as on
postoperative MRI-scans. Data on patients' age, date of
diagnosis, treatment performed, including surgery, radio-
therapy as well as chemotherapy were collected. With
regard to RT, irradiated volumes, radiation doses, treat-
ment failures, second-line treatment and survival were
documented. Histological diagnoses were all reviewed
and categorized according to the World Health Organiza-
tion classification [18].
Radiotherapy treatment planning for FSRT
As described previously, contrast-enhanced CT and MRI
scans were performed in an individual Scotch cast® Mask
fixation for three dimensional treatment planning
[19,20]. The target volume was defined after image corre-
lation of contrast enhanced CT and MR-images with a
slice thickness of 3 mm, using the Voxelplan® software
developed at the German Cancer Research Center [21,22].
Median size of PTV for FSRT was 17.8 ml (range 4.5–281
ml), consisting of the area of contrast enhancement in T1-
weighted MRI-sequences, adding a 1–2 cm safety margin
to include microscopic spread of tumor cells.
All patients gave written informed consent to the treat-
ment.
Follow-up
Patients were seen for follow-up visits 6 weeks after com-
pletion of radiotherapy, then in regular 3 to 6 months
intervals depending on the clinical condition of the
patient. Follow-up visits included a contrast-enhanced
MRI as well as a complete clinical examination including
a thorough neurological assessment. Additional MRI
scans and clinical assessment were performed if new
symptoms developed or deterioration was observed.
Whenever tumor progression and radiation induced
necrosis could not be distinguished by MR-imaging, addi-
tional PET-examinations and MR-spectroscopy were
scheduled. Side effects were documented according to the
Common Toxicity Criteria (CTCAE) Version 3.0.BMC Cancer 2006, 6:222 http://www.biomedcentral.com/1471-2407/6/222
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Statistics
Overall survival was calculated from the time point of pri-
mary diagnosis of ependymoma; survival after re-irradia-
tion was calculated from initiation of FSRT. Progression-
free survival after re-irradiation was calculated from the
initiation of re-irradiation treatment until tumor progres-
sion or death (by any cause), whichever happened first,
using the Kaplan Meier method [23]. The potential prog-
nostic factors age, RT technique, grade, location and
extent of surgical resection were analyzed for the group of
primary localized tumors, using the univariate Cox pro-
portional regression model. Statistical analyses were per-
formed using the software program Statistica 6.0 (StatSoft,
Hamburg, Germany).
Results
Patient characteristics
From October 1989 to December 2004, 19 patients with
histologically diagnosed EPs were treated with Fraction-
ated Stereotactic Radiotherapy (FSRT).
Patient's characteristics are summarized in Table 1. The
median age at primary diagnosis was 15 years (range 1–60
years). Five patients were younger than 4 years of age. The
male:female ratio was 10:9.
Radiotherapy
Deep sedation or general anaesthesia was required for
small children < 5 years who did not tolerate precision
head mask fixation after a training period.
Twelve patients received FSRT as primary postoperative
radiotherapy after surgical resection. In 6 patients irradia-
tion of the posterior fossa was performed with a local
boost to the tumor bed, and in 4 patients the tumor bed
only was irradiated. In two patients, FSRT was applied as
a boost in combination with CSI. A median dose of 54 Gy
(range 46.8 Gy – 64 Gy) was prescribed in a median frac-
tionation of 5 × 1.8 Gy per week for primary local RT
using 6 MeV photons with a linear accelerator. For
patients treated with a boost to the tumor bed, the poste-
rior fossa was treated with a median dose of 45 Gy plus 9
Gy (median) to the tumor bed.
In 7 patients FSRT was performed as re-irradiation at the
time of tumor progression. Patients had been treated pre-
viously with a median dose of 50 Gy (range 40 Gy – 55.2
Gy). The median time between primary irradiation and re-
irradiation was 74 months (range 11 – 406 months).
Imaging performed for treatment planning at the time of
tumor progression was superimposed to the original treat-
ment plans. All recurrent tumors were localized within the
former high dose RT field.
We applied a median dose of 36 Gy (range 20 Gy – 60 Gy)
in a median fractionation of 5 × 1.8 Gy (range 1.8 Gy – 2
Gy) for re-irradiation.
In seven patients CSI was performed. Five of these 7
patients received CSI as a component of primary RT for
localized intracranial tumors, and were irradiated with
FSRT at the time point of local tumor progression. Two
patients received irradiation of the CSI together with FSRT
because of spinal dissemination in the primary situation.
None of the patients received concomitant chemotherapy.
Three patients were treated according to studies per-
formed by the German Pediatric Hematology and Oncol-
ogy Society (GPOH) on multimodal treatment of
Ependymomas (HIT) and received chemotherapy sequen-
tially [24]. A group of three patients received chemother-
apy for tumor progression, including vincristine,
carboplatin, cisplatin, ifosfamide and etoposide.
FSRT was well tolerated by all patients and could be com-
pleted without interruptions due to side effects. No severe
treatment related toxicity > CTC grade 2 for patients
treated with FSRT could be observed.
Twelve patients remain alive after a median follow-up
time of 32 months (7–185 months).
Survival
Overall survival for the total patient collective was 77%
and 64% at 3 and 5 years, respectively (Fig. 1). With
regard to histology, 3 and 5 years overall survival was 87%
and 52% for grade II tumors and 64% and 64% for grade
III tumors, respectively. This difference was not significant
at p = 0.92 (p = 0.54; table 2; Fig. 2). Extent of surgical
Table 1: Patient and tumor characteristics for the entire study 
population (n = 19)
Characteristic No. of patients (%)
age
< 4 5 (26%)
≥ 41 4  ( 7 4 % )
gender
female 9 (47%)
male 10 (53%)
histology
II 12 (63%)
III 7 (37%)
tumor site
supratentorial 4 (21%)
infratentorial 15 (79%)
extent of surgery
total resection 5 (26%)
subtotal resection 14 (74%)BMC Cancer 2006, 6:222 http://www.biomedcentral.com/1471-2407/6/222
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resection did not influence overall survival significantly
(table 2, Fig. 3).
Overall survival in children < 4 years was 100% and 56%
at 3 and 5 years, as opposed to 100% and 85% in patients
≥ 4 years of age (p = 0.04; Fig. 4). Age <18 vs. ≥ 18 also
showed a trend towards a prolonged survival time in
patients older than 18 years of age, which was however
below the significance level (p = 0.39; Fig. 5). Potential
prognostic factors evaluated are listed in table 2. Patients
treated with FSRT for primary irradiation showed an over-
all survival of 100% and 78% at 3 and 5 years after irradi-
ation of the posterior fossa with a boost to the tumor bed,
and the group with treatment of the tumor bed only
showed a survival rate of 100% at 5 years (p = 0.45). The
two patients treated with FSRT and CSI as primary RT died
of tumor progression after 28 and 48 months, respec-
tively.
After re-irradiation with FSRT, survival rates of 83% and
50% at 3-and 5 years, respectively, were obtained.
Local and distant control
Eleven patients developed tumor progression after RT dur-
ing follow-up: these events consisted of local recurrences
in 5 patients, local recurrence and spinal dissemination in
3, and spinal metastases in 3 patients (Fig. 6). All local
recurrences developed within the high dose area of the
former RT-field. No new spinal recurrences developed
after FSRT.
Progression-free survival rates after primary RT as com-
pared to re-irradiation were 64% and 60% at 5 years,
respectively, with local control rates at 3 and 5 years of
60%.
Discussion
In recent years some progress has been made in the ther-
apy of EPs. However, the prognosis for patients with EPs
remains rather poor, and sound evidence regarding the
main prognostic factors and the optimal therapeutic man-
agement strategy for EPs is still lacking.
Table 2: Univariate Analysis of Overall Survival among patients with Grade 2 and Grade Ependymomas (n = 19) treated with 
Fractionated Stereotactic Radiotherapy (FSRT).
Variable 5 yrs. Survival rate 10 yrs. Survival rate P (Cox regression)
all patients 77% 64%
age
< 4 56% 18% 0.04
≥ 48 5 % 7 6 %
gender
female 76% 61% 0.92
male 78% 66%
histology
II 87% 52% 0.92
III 64% 64%
tumor site
supratentorial 100% 0% 0.44
infratentorial 72% 55%
extent of surgery
total resection 100% 67% 0.54
subtotal resection 70% 62%
primary radiotherapy
FSRT+CSI - - 0.45
posterior fossa + boost 78% 78%
tumor bed 100% 100%
Overall survival of patients with histologically confirmed  ependymoma treated with FSRT (77% at 3 years and 64% at  5 years) Figure 1
Overall survival of patients with histologically confirmed 
ependymoma treated with FSRT (77% at 3 years and 64% at 
5 years).BMC Cancer 2006, 6:222 http://www.biomedcentral.com/1471-2407/6/222
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The main primary treatment for EP is surgery, however, a
complete removal of the tumor is rarely possible. Based
on historical data and most recent series, there is a trend
to consider the extent of surgery as a major prognostic fac-
tor [4,5]. Therefore, surgery is commonly the first proce-
dure performed in patients with EP:
Survival rates for childhood EPs reported in the literature
vary from 14% to 70% at 5 years [4,11,16,25-31]. In series
including infratentorial lesions in children only, survival
rates tend to be lower, whereas in series including adult
EPs survival rates are much better [7,32]. In the present
analysis survival rates at 5 and 10 years were 77% and
64%, respectively. In analogy to a variety of published
data, age ≥ 18 seems to be associated with higher overall
survival. Patients ≥ 18 yrs. showed 5 and 10 year overall
survival rates of 88% and 74% as opposed to 68% and
54% in children < 18 years of age. Patients under 4 years
of age demonstrated significantly worse overall survival
times compared to patients ≥ 4 years of age (p = 0.04).
In a variety of studies, histologic grade of the tumor was
also identified as a prognostic factor [16,26,33-38]. How-
ever, a number of studies including the present analysis
did not reveal a significant influence of histologic grade
on treatment outcome. Therefore, the possible correlation
between tumor grade and survival is discussed controver-
sially [4,7,11,16,29,34,39-41]. The different findings
Overall survival broken down by age <18 yrs Figure 5
Overall survival broken down by age <18 yrs. and ≥ 18 yrs. 
(p = 0.39).
Overall survival broken down by the extent of neurosurgical  resection (p = 0.54) Figure 3
Overall survival broken down by the extent of neurosurgical 
resection (p = 0.54).
Overall survival broken down by histology (p = 0.92) Figure 2
Overall survival broken down by histology (p = 0.92).
Overall survival broken down by age < 4 yrs Figure 4
Overall survival broken down by age < 4 yrs. and ≥ 4 yrs (p = 
0.04)BMC Cancer 2006, 6:222 http://www.biomedcentral.com/1471-2407/6/222
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reported might be attributable to sample size, anatomic
tumor location, variability in the definition of anaplasia,
discrepancies in histological diagnosis, and the inclusion
in some series of ependymoblastoma and subependy-
moma, which exhibit different biologic behaviour and
should be analyzed separately [5,42-44].
Furthermore, there is still some controversy about the def-
inition of the optimal treatment volume for EP. Large
studies have shown no survival benefit for patients treated
with whole-brain radiotherapy (WBRT) and irradiation of
the craniospinal axis (CSA) as opposed to RT adminis-
tered to smaller treatment volumes [25,33,45,46]. Kovalic
reported a 10 year survival rate of 75% for patients treated
with local RT as compared to 28% in patients treated with
WBRT [45]. Furthermore, several investigations observed
a lack of statistically significant improvement of outcome
for patients treated with craniospinal irradiation
[25,33,46-48]. However, RT of the CSA was frequently
used in the treatment of high-grade ependymomas due to
their anticipated higher risk of metastatic cerebrospinal
fluid (CSF) seeding [15,25,34,49,50].
However, in several series the most common area of recur-
rence was locally, within the former RT field [25,33,46-
48]. To improve local control, high local doses to the
defined target volume are essential. In the past, a number
of studies have proven a significant correlation between
adequate RT dose and local control. An RT dose between
50 Gy and 60 Gy has been shown to be effective and high
local control rates can be achieved, with 54 Gy being con-
sidered the standard dose and higher doses being pre-
scribed in investigational studies. Garrett et al. showed
overall survival rates of 14% in patients treated with less
than 45 Gy, and a survival rate of 50% in patients treated
with more than 45 Gy [16]. Goldwein et al reported simi-
lar results, with overall survival rates of 18% in patients
treated with less than 45 Gy as compared to survival rates
of 51% in patients treated with doses ≥ 45 Gy [17]. There-
fore, based on the known dose-response relationship of
EP, an improvement in RT techniques might help
improve local control, enabling escalation of local RT
doses while minimizing irradiation of surrounding nor-
mal tissue.
This might be achieved by applying modern RT tech-
niques such as stereotactic radiosurgery (SRS) and frac-
tionated stereotactic radiotherapy (FSRT). High precision
radiotherapy allows the application of high doses to a
defined target volume while sparing normal tissue [19]. In
the past, high precision radiotherapy techniques were not
applied routinely in the management of EP. With SRS,
high local doses are applied in a single fraction[19]. SRS
has been applied in a small number of studies in patients
with EP: Hodgson et al. published the largest series apply-
ing SRS in patients with EP, reporting a 3-year progres-
sion-free survival rate of 22% in 28 paediatric patients.
Jawahar et al. report the outcome of 22 patients treated
with SRS for anaplastic EP, with a 5-year actuarial progres-
sion-free survival rate of 32.4%. A recent study published
by Mansur et al. showed a 3-year relapse free survival rate
of 55.6%, and 3-year overall survival rate of 71.1% in nine
patients with EP treated with SRS [51,52]. However, SRS is
limited to small targets, and therefore this technique is
preferred especially in small recurrent lesions or as a boost
modality for macroscopic residuals in combination with
external beam RT to the tumor bed [51]. With fractionated
stereotactic radiotherapy (FSRT), larger target areas can be
treated while exploiting the biological effect of fractiona-
tion. However, in the literature little data on FSRT in
patients with EP can be found. The results of the present
study support the idea, that FSRT can be applied safely in
patients with primary or recurrent EP. Overall survival and
local control rates are comparable to data found in the lit-
erature and show that FSRT can help improving local con-
trol without leading to an increased rate of marginal
recurrences.
The role of chemotherapy (CHT) in the management of
EP still remains unclear [27,53]. In general, it would be
reserved for patients after failure of previously performed
surgery and RT [35,54,55]. The German Society of Paedi-
atric Hematology and Oncology is conducting a large
study for children with EP, investigating concomitant
chemotherapy with vincristine for WHO grade II and III
EP in children between age 4 and 21 with persisting tumor
after initial RT. Adjuvant chemotherapy with cisplatin,
vincristine, carboplatin and VP16 is recommended for
Grade III EP. In children younger than age of 4, chemo-
therapy including cyclophosphamide, vincristine and
methotrexate is recommended after surgery [24]. Needle
et al. report a benefit in overall survival for patients treated
with carboplatin, vincristine, ifosfamide and etoposide
[56]. In spite of incomplete surgical resection, progres-
sion-free survival after 5 years was 80%. However, hyper-
Eleven patients developed tumor progression after FSRT Figure 6
Eleven patients developed tumor progression after FSRT.BMC Cancer 2006, 6:222 http://www.biomedcentral.com/1471-2407/6/222
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fractionated RT was also included into this regime. Kühl et
al. could demonstrate a rate of 55% of partial or complete
remissions after postoperative CHT before the initiation
of RT in patients with anaplastic EP [57]. In a study per-
formed by the Royal Marsden Hospital, London, 10-year
overall survival was 54% in patients treated with CCNU as
adjuvant CHT as opposed to 34% in patients treated with
RT only [14]. In children < 2–3 years of age, the up-front
application of CHT can help delay the need to initiate RT
[46,58-62]. In the present analysis, three children were
treated according to studies performed by the GPOH on
multimodality treatment of EP (HIT) and received chem-
otherapy sequentially [24]. A group of three patients
received chemotherapy for tumor progression, including
vincristine, carboplatin, cisplatine, ifosfamide and etopo-
side.
The results of large randomized trials evaluating the role
of adjuvant CHT are anticipated.
Conclusion
Until now, no prospective trials including FSRT have been
performed involving children and adults with EP. There-
fore, the current analysis allows us to conclude that FSRT
can be applied in patients with EP without an increased
risk for marginal failures. The main advantage of high pre-
cision RT, i.e. the local application of high doses while
sparing normal tissue, is especially helpful in smaller chil-
dren with respect to early and late neurocognitive seque-
lae and growth deficits caused by irradiation of normal
tissue in young children. FSRT is a useful tool for reirradi-
ation of local recurrences and yields good local control
rates in a considerable proportion of patients.
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